Apollon overexpression promotes cell motility of gliomas, and predicts patients’ poor prognosis

Jian Jiang¹*, Suhua Sun²*, Weijie Wang¹, Dazhao Fang¹, Lianshu Ding¹, Xiaoyang Sun¹

¹Department of Neurosurgery, ²Suhua Sun Endoscopy Center, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an 223300, China

Contributions: (I) Conception and design: L Ding, X Sun; (II) Administrative support: L Ding, X Sun; (III) Provision of study materials or patients: J Jiang, S Sun, W Wang; (IV) Collection and assembly of data: J Jiang; (V) Data analysis and interpretation: J Jiang, S Sun, W Wang, D Fang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

*These authors contributed equally to this work.

Correspondence to: Prof. Lianshu Ding, Xiaoyang Sun. Department of Neurosurgery, Huai’an First People’s Hospital, Nanjing Medical University, 6 Beijing Road West, Huai’an 223300, China. Email: ding.liansu@gmail.com; xiaoyangsun66@sina.com.

Background: Apollon has been reported to play an oncogenic role in various human cancers. Glioma cell line SNB-78 has been reported to express an increased level of apollon and had distinct resistance against several anti-cancer drugs. Here, we aimed to investigate the clinical impact of apollon dysregulation in patients with gliomas, and its functions in malignant phenotypes of glioma cells.

Methods: Apollon expression in human gliomas tissues was examined by immunohistochemistry. Associations between apollon expression and various clinicopathological factors as well as patients’ prognosis were then evaluated. Followed by the transfection of an apollon-specific small interfering RNA in glioma cells, cell migration and invasion were measured by transwell assays in vitro.

Results: Immunostainings of apollon protein were mainly shown in tumor cell cytoplasm of glioma tissues, but weakly or negatively observed in nonneoplastic brain tissues. Statistically, the immunoreactive score (IRS) of apollon protein in glioma tissues was significantly higher than that in the corresponding nonneoplastic brain tissues (P=0.013). Additionally, patients with higher IRS often had advanced World Health Organization (WHO) grade (P=0.001) and shorter overall survival time (P=0.01). Further multivariate analysis identified apollon expression as an independent prognostic factor of glioma patients (P=0.03). Functionally, in vitro experiments revealed that loss of apollon could efficiently suppress migration and invasion of glioma cells.

Conclusions: These findings imply that the dysregulation of apollon may be implicated into tumorigenesis and various pathological changes of human gliomas. Importantly, this protein might be a potential prognostic marker and novel therapeutic target for patients with this tumor.

Keywords: Apollon; glioma; immunohistochemistry; prognosis; malignant phenotype

Submitted Jul 22, 2016. Accepted for publication Nov 03, 2016.
doi: 10.21037/tcr.2016.12.17

View this article at: http://dx.doi.org/10.21037/tcr.2016.12.17

Introduction

As the most frequent and malignant primary tumor type in the central nervous system of the body, human gliomas are characterized by aggressive progression, high recurrence and mortality rate (1,2). Based on the World Health Organization (WHO) criteria, there are four grades of human gliomas, including grade I (pilocytic astrocytoma), grade II (diffuse astrocytoma), grade III (anaplastic astrocytoma), and grade IV (glioblastoma, GBM) (3). As the most common subtype of gliomas, GBM represents a kind
of highly infiltrative, necrosis-prone, mitotically active and cytologically malignant brain tumor (4). In recent years, there have been great advances in standard treatments for glioma patients, such as neurosurgery, chemotherapy and radiotherapy. However, their therapeutic efficacies and patients’ clinical outcome remain unsatisfactory (5). Therefore, it is necessary to understand the molecular mechanisms of human gliomas, to identify new diagnostic and prognostic markers for precise evaluation of patients’ survival, and to develop more efficient therapeutic strategies.

The inhibitors of apoptosis (IAP) family, consisting of eight members with one to three baculovirus inhibitor of apoptosis repeat (BIR) domain, function as endogenous inhibitors of cell apoptosis via binding with caspases and play a crucial role in the regulation of cell death (6). As a member of the human IAP family, apollon, also named as Birc6 or Bruce, is a 528 kDa protein in mammals and consists of a single N-terminal BIR domain and a C-terminal ubiquitin-conjugating domain (7,8). Consistent with other IAP members, apollon can inhibit the activities of caspases-3, 6, 7 and 9 via directly binding to these proteins using its BIR domain (9). Accumulating studies revealed the aberrant expression of apollon protein in various human cancer types, such as acute myeloid leukemia, neuroblastoma, breast cancer, non-small-cell lung cancer, colorectal cancer, cervical cancer, ovarian cancer and prostate cancer, and highlighted its involvement into these malignancies (10-17).

Notably, a previous study of Chen et al. (18) reported that a glioma cell line SNB-78 expressed an increased level of apollon and had distinct resistance against several anti-cancer drugs. However, the role of apollon in human gliomas remains unclear. To address this problem, we aimed to investigate the clinical impact of apollon dysregulation in patients with gliomas, and its functions in malignant phenotypes of glioma cells.

Methods

Ethics statement

The present study was approved by the Research Ethics Committee of Nanjing Medical University, China (ID of ethics approval: NMU2016168). Written informed consent was obtained from all of the patients. All specimens were handled and made anonymous according to the ethical and legal standards.

Patients and tissue samples

A total 96 glioma tissues and 20 nonneoplastic brain tissues, the same as our previous studies (19,20), were collected into the present study. The clinicopathologic features of all the patients were summarized in Supplementary Table S1. The detailed information of this cohort is provided in Supplementary.

Cell culture and transfection

Two human glioma cell lines U251MG and U118MG were purchased from the cell library of the Chinese Academy of Sciences (Shanghai, China). U251MG and U118MG cells were cultured in DMEM (GibCo BRL, Grand Island, NY, USA) supplemented with 10 % fetal bovine serum 2 mM L-glutamine, 100 U/mL penicillin-streptomycin mixture (GibCo BRL) at 37 °C, and 5% CO₂.

When U251MG and U118MG cells reached 80% confluence, the complete medium was replaced with fresh medium before the transfection. To knockdown the expression of apollon, the apollon-specific siRNA (si-apollon) and control siRNA (si-con) were manufactured by Genechem (Shanghai, China). The sequences of apollon-specific siRNA and control siRNA were as following: si-apollon, 5’-AGA AAU UGA CCU UGA GUU A-3’; si-con, 5’-CAA UCU GUA GAU AUA GUG A-3’. U251MG and U118MG cells were transfected with apollon-specific siRNA or control siRNA by Lipofectamine 2000 according to the instruction for users. Transfected cells were collected for western blot and transwell assays after the transfection for 24–48 h.

Immunohistochemistry analysis

Immunohistochemistry analysis was performed to examine the subcellular localization and expression level of apollon protein in 96 glioma tissues and 20 non-neoplastic brain tissues according to the protocols described by our previous studies (19,20). The mouse monoclonal antibody to apollon protein was purchased from Santa Cruz Biotechnology, Inc. (#sc-390616, Santa Cruz, CA, USA).

Two independent experienced pathologists, blinded to the clinicopathological characteristics and clinical outcomes of glioma patients, were employed to evaluate the results of immunostaining. The immunoreactive score (IRS) of each specimen was calculated in a semiquantitative manner based on the percentage of positively stained cells and the intensity of immunostaining. The percentage of
positively stained cells is graded as ‘0’, positively stained cells, <25%; ‘1’, 25% to 75%; and ‘2’, >75%. The intensity of immunostaining is graded as ‘0’, weak yellow; ‘1’, yellow, and ‘2’, dark yellow or brown. Then, the score of the percentage of positively stained cells was multiplied with that of the intensity of immunostaining to yield the IRS score of each sample. Overall, the IRS is graded as: negative (score 0 to 1), low to moderate positive (score 2 to 3), and strong positive (score >3). The number of cells with apollon positive staining showing immunoreactivity in cell cytoplasm in ten representative microscopic fields was counted, and the percentage of positive cells was calculated. The IRS of the two pathologists was compared, and any discrepant scores were trained through reexamining the stainings by both pathologists to achieve a consensus score.

**Western blot analysis**

Expression levels of apollon protein in transfected cells were detected by western blot analysis according to the protocol as described by previous studies (21,22). In brief, the protein samples were extracted from the cell lysates, and the content of the protein samples was determined by Bradford assay. GAPDH was used as an internal control. The primary antibodies were used as following: anti-apollon antibody (mouse monoclonal antibody, #sc-390616, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and anti-GAPDH antibody (mouse monoclonal antibody, #sc-365062, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The band density was measured with a computer-assisted image-analysis system (Adobe Systems, SanJose, CA, USA) and normalized against the expression level of GAPDH protein.

**Cell counting kit-8 (CCK-8) assays in vitro**

Followed by the transfection of apollon-specific siRNA, cell proliferation of U251MG and U118MG cells were examined using a CCK-8 (Beyotime, Nantong, China) according to the users’ instructions. Then, the absorbance at 450 nm was measured on an ELX-800 spectrometer reader (Bio-Tek Instruments, Winooski, USA). All experiments were repeated three times.

**Cell migration and invasion assays in vitro**

Migrated and invaded efficacies of U251MG and U118MG cells were determined using transwell chambers with and without Matrigel™ Basement Membrane Matrix (8 μm pore size, Corning, NY, USA), respectively. In brief, the transfected cells (1×10⁵/well) were resuspended into 100 μL serum-free DMEM medium and then added into the top chamber of the inserts. After that, DMEM medium containing 10% fetal bovine serum was added into the bottom chambers. After 24 h of incubation, the non-migrated-invaded cells in the top chamber were removed, and the migrated/invaded cells in the bottom chamber was fixed and stained with crystal violet. The number of the migrated/invaded cells in five fields was counted under ×200 magnification, and the means for each chamber were determined. All experiments were repeated three times.

**Statistical analysis**

All data analyses were statistically performed using the software of SPSS version 11.0 for Windows (SPSS Inc., IL, USA). Data were expressed as mean ± SD. The difference in IRS of apollon protein between glioma and normal groups was evaluated by the analysis of variance (ANOVA). The associations between apollon protein expression and various clinicopathological characteristics of glioma patients were analyzed by Fisher’s exact test or the χ² test. The prognostic value of apollon expression was statistically assessed by the Kaplan-Meier curve, the log-rank and the Cox proportional hazards model for multivariate survival analysis. The statistical significance of the means in different cell groups was calculated using Student’s t-test. Differences were considered statistically significant when P was less than 0.05.

**Results**

**Overexpression of apollon protein in human glioma and nonneoplastic brain tissues**

Immunostainings of apollon protein were mainly shown in tumor cell cytoplasm of glioma tissues (Figure 1A), but weakly or negatively observed in nonneoplastic brain tissues (Figure 1B). Statistically, the IRS of apollon protein in glioma tissues was significantly higher than that in the corresponding nonneoplastic brain tissues (tumor vs. control: 2.53±0.73 vs. 1.27±0.44, P=0.013, Figure 1C).

To evaluate the clinical impact of apollon protein in human gliomas, all 96 patients were divided into two groups using the median value of apollon’s IRS (2.53): high apollon expression group (n=50, 52.08%, mean ± SD =3.13±0.41) and low apollon expression group (n=46, 47.92%, mean ± SD =1.88±0.35).
Overexpression of apollon protein associates with advanced tumor grade of human gliomas

The associations of apollon protein expression with various clinicopathological characteristics were statistically evaluated and summarized in Table 1. Glioma patients with high apollon expression more frequently had higher WHO grade than those with low apollon (P=0.001). However, no statistically significant associations of apollon expression with age at diagnosis, gender of patients and Karnofsky performance scale (KPS) score was found (both P>0.05, Table 1).

Overexpression of apollon protein predicts poor prognosis of human gliomas

All 96 patients with gliomas were performed follow-up and the median survival of this cohort was 19 months. Glioma patients with high apollon expression had significantly shorter mean survival times than patients with low apollon expression (high vs. low: 16 vs. 28 months). Kaplan–Meier survival curves showed in Figure 2 revealed that overexpression of apollon was significantly associated with poor overall survival (P=0.01). More interestingly, the subgroup analysis also demonstrated that the high-grade glioma patients with high apollon expression had shorter overall survival than those with low apollon expression (P<0.01, Figure 3A). However, there was no difference with statistical significance between high and low apollon expression groups for low-grade glioma patients (Figure 3B).

After the construction of a multivariate Cox proportional hazard model, the results found that apollon expression (P=0.03), WHO grade (P=0.009) and KPS score (P=0.02) seemed to be independent prognostic indicators (Table 2).

Loss of apollon expression suppresses cell proliferation, migration and invasion of glioma cells

As shown in Figure 4 based on the results of western blot
Table 1  Associations between apollon immunostaining and various clinicopathological characteristics of human gliomas

<table>
<thead>
<tr>
<th>Parameters</th>
<th>No. patients</th>
<th>Apollon expression levels (n, %)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Low</td>
<td>High</td>
</tr>
<tr>
<td>Histological type/WHO</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>grade</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Astrocytoma/2</td>
<td>10</td>
<td>10 (100.00)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>Oligodendroglioma/2</td>
<td>8</td>
<td>8 (100.00)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>Anaplastic astrocytoma/3</td>
<td>19</td>
<td>10 (52.63)</td>
<td>9 (47.37)</td>
</tr>
<tr>
<td>Anaplastic oligodendroglioma/3</td>
<td>16</td>
<td>8 (50.00)</td>
<td>8 (50.00)</td>
</tr>
<tr>
<td>GBM/4</td>
<td>43</td>
<td>13 (23.26)</td>
<td>33 (76.74)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td>0.218</td>
<td></td>
</tr>
<tr>
<td>&lt;55</td>
<td>40</td>
<td>20 (50.00)</td>
<td>20 (50.00)</td>
</tr>
<tr>
<td>≥55</td>
<td>56</td>
<td>26 (46.43)</td>
<td>30 (53.57)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td>0.299</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>61</td>
<td>29 (47.54)</td>
<td>32 (52.46)</td>
</tr>
<tr>
<td>Female</td>
<td>35</td>
<td>17 (48.57)</td>
<td>18 (51.43)</td>
</tr>
<tr>
<td>KPS</td>
<td></td>
<td>0.056</td>
<td></td>
</tr>
<tr>
<td>≥80</td>
<td>62</td>
<td>32 (51.61)</td>
<td>30 (48.39)</td>
</tr>
<tr>
<td>&lt;80</td>
<td>34</td>
<td>14 (41.18)</td>
<td>20 (58.82)</td>
</tr>
<tr>
<td>Tumor location</td>
<td></td>
<td>0.058</td>
<td></td>
</tr>
<tr>
<td>Frontal</td>
<td>43</td>
<td>23 (53.49)</td>
<td>20 (46.51)</td>
</tr>
<tr>
<td>Nonfrontal</td>
<td>53</td>
<td>23 (43.40)</td>
<td>30 (56.60)</td>
</tr>
</tbody>
</table>

WHO, World Health Organization; KPS, Karnofsky performance scale.

Figure 2  Kaplan–Meier survival curves for apollon protein expression in human gliomas.

Figure 3  Kaplan–Meier survival curves for apollon protein expression in subgroup analysis based on WHO grade of glioma patients. (A) High-grade glioma patients with high apollon expression had shorter overall survival than those with low apollon expression (P<0.01); (B) there was no difference with statistical significance between high and low apollon expression groups for low-grade glioma patients.

Jiang et al. Apollon in glioma analysis, the expression levels of apollon protein in si-apollon transfected U251MG and U118MG cells were markedly decreased, compared to those in cells transfected with control siRNA (P<0.001). CCK-8 and transwell assays respectively showed that the decreased expression of apollon protein could efficiently suppress cell proliferation, migration and invasion abilities of U251MG and U118MG cells compared to control group (all P<0.05, for CCK-8
Table 2: Prognostic value of apollon expression in multivariate analysis by Cox regression

<table>
<thead>
<tr>
<th>Features</th>
<th>Wald¹</th>
<th>df²</th>
<th>P</th>
<th>Exp (B)</th>
<th>95.0% CI for Exp (B)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Lower</td>
</tr>
<tr>
<td>Apollon expression</td>
<td>16.68</td>
<td>1</td>
<td>0.03</td>
<td>2.98</td>
<td>1.52</td>
</tr>
<tr>
<td>WHO grade</td>
<td>22.39</td>
<td>1</td>
<td>0.009</td>
<td>2.02</td>
<td>1.04</td>
</tr>
<tr>
<td>KPS score</td>
<td>13.78</td>
<td>1</td>
<td>0.02</td>
<td>2.65</td>
<td>1.36</td>
</tr>
</tbody>
</table>

¹, "Wald" refers to Chi-square value; ², "df" refers to degree of freedom. WHO, World Health Organization; KPS, Karnofsky performance scale.

Figure 4: Western blot analysis on the expression levels of apollon protein in si-apollon or si-con transfected U251MG (A) and U118MG (B) cells.

Figure 5: CCK-8 assays on the effects of apollon protein to cell proliferation of U251MG (A) and U118MG (B) cells followed by the transfection of si-apollon or si-con.

Discussion

Human gliomas represent an aggressive malignancy featured by limited efficient therapeutic strategies and poor prognosis. Therefore, it is of great clinical significance to identify novel prognostic markers and effective therapeutic targets for the treatment of this malignancy. In the present study, we initially examined the sub-cellular localization and expression pattern of apollon protein in human glioma tissues. As a result, the immunostainings of apollon protein

assay, Figure 5; for transwell assay, Figure 6).
were mainly shown in tumor cell cytoplasm of glioma tissues, but weakly or negatively observed in nonneoplastic brain tissues. Statistically, its IRS in glioma tissues was dramatically increased when compared to that in the corresponding nonneoplastic brain tissues. In addition, patients with higher IRS often had advanced WHO grade and shorter overall survival time. Further multivariate analysis identified apollon expression as an independent
prognostic factor of glioma patients. Functionally, in vitro experiments revealed that loss of apollon could efficiently suppress proliferation, migration and invasion of glioma cells. These findings highlight the crucial roles of apollon expression in tumor progression, patients’ prognosis and tumor cell motility of human gliomas.

As the largest member of the human IAP family, apollon contains a single N-terminal BIR domain and a C-terminal ubiquitin-conjugating domain, which exerts chimeric E2/E3 ubiquitin ligase activity and antiapoptotic activity (6). Growing evidence shows that the aberrant expression of apollon may play critical roles in tumorigenesis and tumor progression of various human cancer types. For example, Schläfli et al. (10) found significantly lower apollon levels in particular AML subtypes as compared to granulocytes from healthy donors, and described that the knockdown of apollon in acute promyelocytic leukemia cells could distinctly impair neutrophil differentiation, but not cell viability. In contrast, Low et al. (11) reported the elevated apollon protein expression in prostate cancer cell lines and clinical specimens as distinct from their benign counterparts; The authors also determined that the reduction of apollon expression in PCa cell lines could lead to a marked reduction in cell proliferation which was associated with an increase in apoptosis and a decrease in autophagosome formation; Hu et al. (12) suggested that apollon overexpression might be a predictor of poor prognosis in colorectal cancer; Dong et al. (13) revealed that the increased expression of apollon protein in non-small-cell lung cancer tissues might be closely correlated with cancer recurrence and chemoresistance of patients. These reports imply that apollon may function as either an oncogenic factor or a tumor suppressor depending on different cancer types.

Consistent with the previous studies on neuroblastoma (14) and glioma cell line (18), our data here also found the overexpression of apollon protein in clinical glioma tissue specimens and determine its associations with advanced tumor grades and unfavorable patients’ prognosis. Notably, our data, obtained by knock-downing apollon expression, described a role for apollon in modulating the biological properties of glioma cells, including proliferation, migration and invasion in vitro. Loss of this protein led to the suppression of cell motility dramatically.

**Conclusions**

In conclusion, our findings in the present study imply that the dysregulation of apollon may be implicated into tumorigenesis and various pathological changes of human gliomas. Importantly, this protein might be a potential prognostic marker and novel therapeutic target for patients with this tumor. However, an increasing study has identified several markers for determining the prognosis of glioma patients, such as IDH, MGMT, ATRX, P53, etc. Therefore, the correlation between these established glioma markers and apollon are required to be evaluated, in order to confirm the role of apollon as an independent prognostic marker.

**Acknowledgements**

**Funding:** This work was supported by research grants from the Science and Technology Development Foundation of Huai’an to Dr. lianshu Ding (China, No. HAS2015018).

**Footnote**

**Conflicts of Interest:** The authors have no conflicts of interest to declare.

**Ethical Statement:** The study was approved by the Research Ethics Committee of Nanjing Medical University, (NMU2016168) and written informed consent was obtained from all patients.

**References**


Patients and tissue samples

A total of ninety-six glioma samples were obtained from 96 Chinese patients with gliomas of different grades. Patient characteristics, including the KPS score, were collected before the initial surgery. After surgical resection of their tumors, patients with a high-grade glioma received a course of external beam radiation therapy (standard doses: 40 Gy to the tumor with 3-μm margins, 20 Gy boost to the whole brain) and nitrosourea-based chemotherapy during the course of the disease. Surgically resected tissues were frozen immediately and stored at –80 °C until processing. Tumors were classified histopathologically according to the WHO classification. No patients recruited in this study had chemotherapy or radiotherapy before the surgery. The clinicopathologic features of all the patients were summarized in Supplementary Table S1. In addition, 20 non-neoplastic brain specimens, for use as controls for the immunohistochemistry, were obtained from patients with traumatic brain injury at the site of decompression.

For the analysis of survival and follow-up, the date of surgery was used to represent the beginning of the follow-up period. All patients who died from diseases other than glioma or from unexpected events were excluded from the case collection. Follow-ups were terminated until May 28, 2009. The median follow-up was 42 months (range, 1–96 months). Treatment modalities after relapse were given according to a uniform guideline as described.

<table>
<thead>
<tr>
<th>WHO grade</th>
<th>No. patients</th>
<th>Histological type</th>
<th>No. patients</th>
<th>Mean age (yrs)</th>
<th>Gender</th>
<th>Tumor location</th>
<th>KPS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Male</td>
<td>Female</td>
<td>Frontal</td>
<td>Nonfrontal</td>
</tr>
<tr>
<td>Grade II</td>
<td>18</td>
<td>Astrocytoma</td>
<td>10</td>
<td>50.6</td>
<td>5</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oligodendrogloma</td>
<td>8</td>
<td>51.1</td>
<td>5</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Grade III</td>
<td>35</td>
<td>Anaplastic astrocytoma</td>
<td>19</td>
<td>50.2</td>
<td>11</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anaplastic oligodendrogloma</td>
<td>16</td>
<td>50.4</td>
<td>9</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>Grade IV</td>
<td>43</td>
<td>GBM</td>
<td>43</td>
<td>51.2</td>
<td>31</td>
<td>12</td>
<td>17</td>
</tr>
<tr>
<td>Total</td>
<td>96</td>
<td></td>
<td>96</td>
<td>50.9</td>
<td>61</td>
<td>35</td>
<td>43</td>
</tr>
</tbody>
</table>

GBM, glioblastoma; KPS, Karnofsky performance scale.